Macrogenics (Macrogenics) LT-Debt-to-Total-Asset : 0.10 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Macrogenics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.10.

Macrogenics's long-term debt to total assets ratio declined from Dec. 2022 (0.11) to Dec. 2023 (0.10). It may suggest that Macrogenics is progressively becoming less dependent on debt to grow their business.

Macrogenics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Macrogenics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics LT-Debt-to-Total-Asset Chart

Macrogenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.07

0.06

0.11

0.10

Macrogenics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.09	0.10	0.09	0.10

Macrogenics LT-Debt-to-Total-Asset Calculation

Macrogenics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	30.196	/	298.418
	=	0.10

Macrogenics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	30.196	/	298.418
	=	0.10

Macrogenics (NAS:MGNX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Macrogenics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Macrogenics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Macrogenics (Macrogenics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

M55:Germany

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

Executives

Ezio Bonvini	officer: Sr VP, Research & CSO	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz	director
Jeffrey Stuart Peters	officer: Acting General Counsel	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Margaret Liu	director	C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
James Karrels	officer: SVP, CFO and Secretary	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
William K Heiden	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Thomas Spitznagel	officer: Sr VP, BPD & Manufacturing	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Eric Blasius Risser	officer: Sr VP & Chief Business Officer	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth Galbraith	director	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck	officer: Chief Medical Officer	12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949